Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug~2. Glycosylated haemoglobin (HbA1c) 6.0 - 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug~3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone~4. HbA1c 6.5 - 10.0% at beginning of the placebo run-in phase~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA)~2. Impaired hepatic function~3. Renal failure or renal impairment~4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening~5. Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 5mg, once daily (Type: EXPERIMENTAL): patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
- Glimepiride (Type: ACTIVE_COMPARATOR): patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)

Based on this trial design, predict the completion outcome and termination type (if applicable).